Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $21.00.

A number of research analysts have recently weighed in on the company. HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th.

Institutional Trading of Artiva Biotherapeutics

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $166,000. Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $7,435,000. Barclays PLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $304,000. Geode Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth approximately $4,774,000. Finally, Wellington Management Group LLP purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at $2,912,000.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $10.67 on Monday. The business’s 50-day simple moving average is $11.37. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Sell-side analysts predict that Artiva Biotherapeutics will post -4.68 EPS for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.